These results indicate that PCA exhibits strong binding affinity toward key target proteins TLR4, MyD88, IKKβ, NF‐κB p65 and MurF1, suggesting that the therapeutic effect of PCA on skeletal muscle atrophy may be mediated through the TLR4/MyD88/NF‐κB signalling pathway. The gene discussed is TRIM63; the disease is muscular atrophy.